Find information on thousands of medical conditions and prescription drugs.

Tenuate

Diethylpropion (Tenuate®) is a sympathomimetic stimulant drug marketed as an appetite suppressant. Chemically, it is the N,N-diethyl analog of cathinone. Its mechanism of action is similar to other appetite suppressants such as sibutramine, phentermine and dextroamphetamine.

Diethylpropion is manufactured in 25 mg tablets and 75 mg controlled-release tablets.

Diethylpropion is classified as a Schedule IV controlled substance in the United States.


Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
Oxytetracycline
Phentermine
Tacrine
Tacrolimus
Tagamet
Talbutal
Talohexal
Talwin
Tambocor
Tamiflu
Tamoxifen
Tamsulosin
Tao
Tarka
Taurine
Taxol
Taxotere
Tazarotene
Tazobactam
Tazorac
Tegretol
Teicoplanin
Telmisartan
Temazepam
Temocillin
Temodar
Temodar
Temozolomide
Tenex
Teniposide
Tenoretic
Tenormin
Tenuate
Terazosin
Terbinafine
Terbutaline
Terconazole
Terfenadine
Teriparatide
Terlipressin
Tessalon
Testosterone
Tetrabenazine
Tetracaine
Tetracycline
Tetramethrin
Thalidomide
Theo-24
Theobid
Theochron
Theoclear
Theolair
Theophyl
Theophyl
Theostat 80
Theovent
Thiamine
Thiomersal
Thiopental sodium
Thioridazine
Thorazine
Thyroglobulin
Tiagabine
Tianeptine
Tiazac
Ticarcillin
Ticlopidine
Tikosyn
Tiletamine
Timolol
Timoptic
Tinidazole
Tioconazole
Tirapazamine
Tizanidine
TobraDex
Tobramycin
Tofranil
Tolazamide
Tolazoline
Tolbutamide
Tolcapone
Tolnaftate
Tolterodine
Tomoxetine
Topamax
Topicort
Topiramate
Tora
Toradol
Toremifene
Tracleer
Tramadol
Trandate
Tranexamic acid
Tranxene
Tranylcypromine
Trastuzumab
Trazodone
Trenbolone
Trental
Trest
Tretinoin
Triacetin
Triad
Triamcinolone
Triamcinolone hexacetonide
Triamterene
Triazolam
Triclabendazole
Triclosan
Tricor
Trifluoperazine
Trilafon
Trileptal
Trimetazidine
Trimethoprim
Trimipramine
Trimox
Triprolidine
Triptorelin
Tritec
Trizivir
Troglitazone
Tromantadine
Trovafloxacin
Tubocurarine chloride
Tussionex
Tylenol
Tyrosine
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


Obesity
From OB/GYN News, 9/1/04 by Mitchel L. Zoler

Withdrawal of the popular obesity drugs fenfluramine and dexfenfluramine (Redux) from the U.S. market in 1997 left Americans hungry for new obesity drugs with long-term efficacy. They're still waiting, as their waistlines continue to grow.

In other words, there's no weight-loss drug now available that's close to ideal. Obesity plus overweight remains the most common nutritional disorder in the United States, with a prevalence that has ballooned by 75% since 1980. Available pharmacologic agents are rarely effective for weight loss or for improving obesity-related conditions unless they're used as part of a comprehensive approach that also includes dietary and lifestyle changes and behavioral therapy. Patients often regain weight after stopping treatment. But despite these shortcomings, some type of drug therapy is recommended for patients with a body mass index of 27 kg/[m.sup.2] or higher and obesity-related morbidity, and for everyone with a BMI of 30 kg/[m.sup.2] or higher.

Orlistat and sibutramine are the newest obesity drugs and are the only ones approved for long-term use. Both have been studied for at least 2 years. Along with behavioral interventions, these drugs are generally modestly effective for weight loss and maintenance, compared with placebo.

Behavioral interventions--which can be as simple as support group participation or consulting a registered dietitian--enhance the effects of treatment. In one study with 57 patients, loss of at least 15% of body weight was the benchmark for success. This goal was reached by 15% of patients treated with a drug only, 25% of those treated with a drug plus participation in a lifestyle intervention group, and 60% of patients who got the drug and participated in both lifestyle and behavioral intervention groups.

With the exception of orlistat, which is not absorbed into the systemic circulation, obesity drugs should be avoided by women who are pregnant or breast-feeding. A number of experts also don't prescribe orlistat during pregnancy.

Several other drugs are in development. Cannabinoid receptor blockers, now in phase III trials, may become the first approved appetite-reducing drugs that are not stimulants. Topiramate and other antiepileptics are being studied for obesity and may be particularly good for patients with bingeing disorders.

--Mitchel L. Zoler, Editor

--Sharon Worcester, Writer

COPYRIGHT 2004 International Medical News Group
COPYRIGHT 2004 Gale Group

Return to Tenuate
Home Contact Resources Exchange Links ebay